Department of Neurosurgery, Zhumadian Central Hospital, Zhumadian, Henan, P.R. China.
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.
Oncol Res. 2018 Mar 5;26(2):307-313. doi: 10.3727/096504017X15088061795756. Epub 2017 Oct 24.
Recently, long noncoding RNAs (lncRNAs) have emerged as new gene regulators and prognostic markers in several cancers, including glioma. Here we focused on lncRNA LUCAT1 on the progression of glioma. qRT-PCR was used to determine the expression of LUCAT1 and miR-375 in glioma tissues and cells. MTT and Transwell invasion assays were performed to determine the function of LUCAT1 in glioma progression. The bioinformatics tool DIANA was used to predict the targets of LUCAT1. Pearson's correlation analysis was performed to explore the correlation between LUCAT1 and miR-375. In the present study, we showed that LUCAT1 was substantially upregulated in glioma tissues and cells. LUCAT1 inhibition significantly suppressed the proliferation and invasion of glioma cells. Subsequently, DIANA showed that miR-375 was predicted to contain the complementary binding sites to LUCAT1. Luciferase reporter assay showed that miR-375 directly targeted LUCAT1. In addition, we found that miR-375 was downregulated in glioma tissues and negatively correlated with LUCAT1 expression in glioma tissues. Furthermore, the results showed that miR-375 could rescue the function of LUCAT1 in glioma progression. The lncRNA LUCAT1 was critical for the proliferation and invasion of glioma cells by regulating miR-375. Our findings indicated that LUCAT1 might offer a potential novel therapeutic target for the treatment of glioma.
最近，长链非编码 RNA（lncRNA）已成为包括神经胶质瘤在内的多种癌症中的新基因调控因子和预后标志物。在这里，我们重点关注 lncRNA LUCAT1 在神经胶质瘤进展中的作用。qRT-PCR 用于确定神经胶质瘤组织和细胞中 LUCAT1 和 miR-375 的表达。MTT 和 Transwell 侵袭实验用于确定 LUCAT1 在神经胶质瘤进展中的作用。生物信息学工具 DIANA 用于预测 LUCAT1 的靶标。Pearson 相关分析用于探索 LUCAT1 与 miR-375 之间的相关性。在本研究中，我们表明 LUCAT1 在神经胶质瘤组织和细胞中显著上调。LUCAT1 抑制显著抑制神经胶质瘤细胞的增殖和侵袭。随后，DIANA 表明 miR-375 被预测含有与 LUCAT1 互补结合的位点。荧光素酶报告实验表明 miR-375 直接靶向 LUCAT1。此外，我们发现 miR-375 在神经胶质瘤组织中下调，并与神经胶质瘤组织中 LUCAT1 的表达呈负相关。此外，结果表明 miR-375 可以挽救 LUCAT1 在神经胶质瘤进展中的功能。LUCAT1 通过调节 miR-375 对神经胶质瘤细胞的增殖和侵袭至关重要。我们的研究结果表明，LUCAT1 可能为神经胶质瘤的治疗提供一个潜在的新的治疗靶点。
